Companies · Biotechnology

Kineta, Inc./De

SEATTLE · Biotechnology

Diligence memoA one-page analyst read on Kineta, Inc./De — recommendation, valuation, rhythm, risks.
$141.6M
Total raised · real
6
Rounds
0.4×
Latest step-up
Top 7%
Sector rank · raised
Series C
Latest stage · inferred · Tue Oct 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Kineta, Inc./De looks under-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.07× the median modeled value of Series C Biotechnology companies in 2022–2024 (111 peers) — value vs value, same stage and era.
At-risk
  • Last raise 2.7 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Kineta, Inc./De is one of 4293 Biotechnology companies tracked from SEATTLE. By capital raised it ranks among the largest (ahead of 94% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2023-10-03
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries C · 2008-08-15 Raised $71M (real) Modeled valuation $2.9B (est)Series C2008Series C · 2014-07-31 Raised $5.0M (real) Modeled valuation $205M (est)Series C2014Series A · 2014-07-31 Raised $15M (real) Modeled valuation $542M (est)Series A2014Seed · 2014-07-31 Raised $3.0M (real) Modeled valuation $134M (est)Seed2014Series C · 2015-09-01 Raised $22M (real) Modeled valuation $901M (est)Series C2015Series C · 2020-12-22 Raised $34M (real) Modeled valuation $1.1B (est)Series C2020Series C · 2022-12-16 Raised $7.5M (real) Modeled valuation $120M (est)Series C2022Series C · 2023-10-03 Raised $2.9M (real) Modeled valuation $34M (est)Series C2023+$5.0M+$15M+$3.0M+$22M+$34M+$7.5M+$2.9MCumulative $160M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series C$70.6M · 2008
Series C extension$5.0M · 2014
Bridge · Series C-stage$15.0M · 2014smaller follow-on
Bridge · Series C-stage$3.0M · 2014smaller follow-on
Series C extension$22.0M · 2015
Series C extension$33.6M · 2020
Series C extension$7.5M · 2022
Series C extension$2.9M · 2023

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Series B — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 60%.

Modeled valuation trajectory
$34.3M
Base estimate est.
$8.9M
Conservative case
$57.7M
Upside case
$19.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series C · modeled $2.9B · 2008-08-152008Series C · modeled $204.8M · 2014-07-31Series A · modeled $542.3M · 2014-07-31Seed · modeled $133.8M · 2014-07-31Series C · modeled $901.1M · 2015-09-01Series C · modeled $1.1B · 2020-12-22Series C · modeled $120.4M · 2022-12-16Series C · modeled $34.3M · 2023-10-032023
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
62%
Survival probability
46% low · 72% high
1.46×/yr
Annual markup
1.68×/yr upside case
2.8 yr
Elapsed time used
2.8 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
26 mo
Avg between rounds
$9.4M/yr
Capital velocity
17.9 yr
On record since
2008
First round
8
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 20× above median
This company$141.6M
Sector median$7.2M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.1× of median
This company$2.9M
Sector median$46.5M
Modeled value — vs sector median (estimate, all stages) 0.5× of median
This company$34.3M
Sector median$64.2M

Raised more than 94% of sector peers (real $). Modeled value above 38% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #106 of 111.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Dianthus Therapeutics, Inc. · Series C Raised $121.5M · modeled $2.1B (est)Satellite Biosciences, Inc. · Series C Raised $101.5M · modeled $1.8B (est)Deepcell, Inc. · Series C Raised $96.9M · modeled $1.7B (est)Ventus Therapeutics U.S., Inc. · Series C Raised $186.8M · modeled $1.6B (est)Morphic Holding, Inc. · Series C Raised $200.6M · modeled $1.5B (est)Genleap Ai Inc. · Series C Raised $100.0M · modeled $1.5B (est)Dren Bio, Inc. · Series C Raised $93.1M · modeled $1.3B (est)Lenz Therapeutics, Inc. · Series C Raised $136.2M · modeled $1.2B (est)eyeBrain Medical, Inc. · Series C Raised $126.3M · modeled $1.2B (est)A2 Biotherapeutics, Inc. · Series C Raised $143.1M · modeled $1.2B (est)Invetx, Inc. · Series C Raised $70.7M · modeled $1.2B (est)Hexagon Bio Inc. · Series C Raised $148.6M · modeled $1.2B (est)Kineta, Inc./De (this company) Raised $141.6M · modeled $34.3M (est)Kineta, Inc./De
CompanyStageRaised · realValue · estvs peer med.
Dianthus Therapeutics, Inc.Series C$121.5M$2.1B4.22×
Satellite Biosciences, Inc.Series C$101.5M$1.8B3.63×
Deepcell, Inc.Series C$96.9M$1.7B3.38×
Ventus Therapeutics U.S., Inc.Series C$186.8M$1.6B3.14×
Morphic Holding, Inc.Series C$200.6M$1.5B3.04×
Genleap Ai Inc.Series C$100.0M$1.5B3.00×
Dren Bio, Inc.Series C$93.1M$1.3B2.70×
Lenz Therapeutics, Inc.Series C$136.2M$1.2B2.49×
eyeBrain Medical, Inc.Series C$126.3M$1.2B2.45×
A2 Biotherapeutics, Inc.Series C$143.1M$1.2B2.42×
Invetx, Inc.Series C$70.7M$1.2B2.36×
Hexagon Bio Inc.Series C$148.6M$1.2B2.36×
Kineta, Inc./De this companySeries C$141.6M$34.3M0.07×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series C$70.6M2008-08-15$470.8M$2.9B85%
Series C$5.0M2014-07-31$33.3M$204.8M85%
Series A$15.0M2014-07-31$68.2M$542.3M85%
Seed$3.0M2014-07-31$15.1M$133.8M85%
Series C$22.0M2015-09-01$146.7M$901.1M85%
Series C$33.6M2020-12-22$224.0M$1.1B90%
Series C$7.5M2022-12-16$50.0M$120.4M90%
Series C$2.9M2023-10-03$19.3M$34.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series C$70.6M2008-08-15
    • First recorded raise — entered as Series C.
    • 7 investors on this round.
  2. Series C$5.0M2014-07-31
    • Raised again after 71 mo — slower than the ~14 mo sector norm.
    • Round 14.1× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 7 investors on this round.
  3. Series A$15.0M2014-07-31
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.0× larger than the prior — scaling up.
    • 8 investors on this round.
  4. Seed$3.0M2014-07-31
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 5.0× smaller than the prior — bridge or down round.
    • 5 investors on this round.
  5. Series C$22.0M2015-09-01
    • Raised 13 mo later, in step with the ~14 mo sector norm.
    • Round 7.3× larger than the prior — scaling up.
    • 9 investors on this round.
  6. Series C$33.6M2020-12-22
    • Raised again after 64 mo — slower than the ~14 mo sector norm.
    • Round 1.5× larger than the prior — scaling up.
    • 16 investors on this round.
  7. Series C$7.5M2022-12-16
    • Raised again after 24 mo — slower than the ~14 mo sector norm.
    • Round 4.5× smaller than the prior — bridge or down round.
    • 17 investors on this round.
  8. Series C$2.9M2023-10-03
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round 2.6× smaller than the prior — bridge or down round.
    • 1 investor on this round.
Intelligence
2025 ~Q4
Modeled next raise · ~26mo cadence
$2.9M
Modeled next size est.range $2.9M$4.6M
0.4×
Last step-up
$9.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Christopher Mirabelli5 other2014-07
JEFFREY GOLDBERG5 other2014-07
M. James Barrett5 other2014-07
STEPHEN KNIGHT5 other2014-07
Christopher Walsh4 other2014-07
BERNARD DAVITIAN3 other2014-07
Christopher K. Mirabelli3 other2008-08
Marion R Foote3 other2022-12
MICHAEL CASEY3 other2014-07
Shawn Iadonato3 other2022-12
Christopher T. Walsh2 other2008-08
David Arkowitz2 other2022-12
Kim C. Drapkin2 other2020-12
LAUREN SILVERMAN2 other2014-07
N. Anthony Coles2 other2020-12
Patricia L. Allen2 other2020-12
Raymond Bartoszek2 other2022-12
RICHARD PETERS2 other2020-12
Craig W. Philips1 other2022-12
Jeffery W. Kelly1 other2008-08
Kimberlee C. Drapkin1 other2023-10
Meenu Chhabra1 other2014-07
Raymond R. Bartoszek1 other2023-10
Richard A. Heyman1 other2020-12
Registry & provenance

Kineta, Inc./De is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1445283
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Kineta, Inc.BiotechnologySeries B$87.1M$47.0Mnetwork4 shared operators · same sector
Jounce Therapeutics, Inc.BiotechnologySeries C$91.0M$1.3Bnetwork2 shared operators · same sector · same stage
Deciphera Pharmaceuticals, LLCBiotechnologySeries C$142.9M$2.1Bnetwork1 shared operator · same sector · same stage
Vanqua Bio, Inc.BiotechnologySeries C$136.0M$462.9Mnetwork1 shared operator · same sector · same stage
Protego BiopharmaBiotechnologySeries C$85.0M$179.4Mnetwork1 shared operator · same sector · same stage
Leap Therapeutics, Inc.PharmaceuticalsSeries C$105.1M$1.1Bnetwork2 shared operators · same stage
Yumanity Holdings, LLCOther Health CareSeries C$103.8M$494.4Mnetwork2 shared operators · same stage
Semma Therapeutics, Inc.BiotechnologySeries D+$129.3M$4.7Bnetwork1 shared operator · same sector
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Kineta, Inc.BiotechnologySeries B$47.0M98%
Kineta Immuno-Oncology, LLCBiotechnologyPre-Seed$13.2M89%
Kiniksa Pharmaceuticals, Ltd.BiotechnologySeries A$318.1M88%
KinaRX, LLCBiotechnologyPre-Seed$7.2M86%
Metsera, Inc.BiotechnologySeries D+$2.1B86%
Mitera Biosciences Inc.BiotechnologySeed$9.4M84%
Vineti, Inc.BiotechnologySeries C$2.8B83%
Ekso Bionics Holdings, Inc.BiotechnologySeries C$113.4M83%
Frequently asked
How much funding has Kineta, Inc./De raised?
Kineta, Inc./De has raised approximately $141.6M in disclosed capital across 6 recorded financing rounds, aggregated from public filings.
What is Kineta, Inc./De's estimated valuation?
Provath's modeled valuation for Kineta, Inc./De is approximately $34.3M (modeled range $8.9M–$57.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Kineta, Inc./De at?
Kineta, Inc./De's latest modeled financing stage is Series C. Its most recent recorded round closed around Tue Oct 03.
What does Kineta, Inc./De do and where is it based?
Kineta, Inc./De operates in the Biotechnology sector, based in SEATTLE.
Explore related

See where Kineta, Inc./De sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Kineta, Inc./De, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.